Researchers have discovered subcellular signs of young-onset Parkinson’s disease that emerge before symptoms arise. Additionally, further testing has revealed a drug that may reverse these cellular abnormalities.
Functional neuromuscular organoids have been developed that self-organize into spinal cord neurons and muscle tissue, paving the way for a new avenue to study human neuromuscular system development and disease.
In this research article from the Journal of Comparative Effectiveness Research, the authors assess the real-world outcomes among patients with Duchenne muscular dystrophy receiving deflazacort or prednisone in real-world practice.
Having previously been demonstrated to allow dopamine replenishment, results of a recent clinical trial suggest nilotinib could be a safe and well-tolerated treatment for individuals with Parkinson’s disease.
Discover more about an ongoing, multicenter registry that provides real-world evidence regarding ataluren use in nonsense mutation Duchenne muscular dystrophy patients in this research article.
Researchers discover a potential approach to prevent the progression of many neurological diseases.
October babies are more likely to develop the syndrome, according to a study presented at the Congress of the European Academy of Neurology (Amsterdam, The Netherlands).
Researchers discover that the drug, pyrimethamine, may reduce disease progression in patients with inherited amyotrophic lateral sclerosis (ALS).
Today marks World MS Day, a day to bring the global MS community together to raise awareness, celebrate pioneering research, and look ahead to the future.